What is Briacell Therapeutics Corp?
, a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 26.72M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.